Stockreport

Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF -- Continued Progress in the OPTIC Phase 1 Clinical Trial -- Patients Receiving Single Intravitreal Injection of ADVM-022 Dosed at 2 x 10^11 vg/eye MENLO PARK, [Read more]